Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

MLA

Fenaux, Pierre, et al. “Prolonged Survival with Improved Tolerability in Higher-Risk Myelodysplastic Syndromes: Azacitidine Compared with Low Dose Ara-C.” British Journal of Haematology, vol. 149, no. 2, Apr. 2010, pp. 244–49. EBSCOhost, https://doi.org/10.1111/j.1365-2141.2010.08082.x.

APA

Fenaux, P., Gattermann, N., Seymour, J. F., Hellström-Lindberg, E., Mufti, G. J., Duehrsen, U., Gore, S. D., Ramos, F., Beyne-Rauzy, O., List, A., McKenzie, D., Backstrom, J., & Beach, C. L. (2010). Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. British Journal of Haematology, 149(2), 244–249. https://doi.org/10.1111/j.1365-2141.2010.08082.x

Chicago

Fenaux, Pierre, Norbert Gattermann, John F Seymour, Eva Hellström-Lindberg, Ghulam J Mufti, Ulrich Duehrsen, Steven D Gore, et al. 2010. “Prolonged Survival with Improved Tolerability in Higher-Risk Myelodysplastic Syndromes: Azacitidine Compared with Low Dose Ara-C.” British Journal of Haematology 149 (2): 244–49. doi:10.1111/j.1365-2141.2010.08082.x.